Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports

This analysis of the FAERS database found use of hydroxychloroquine and chloroquine was associated with a higher reporting rate of major CV adverse events, including cardiomyopathy (reporting OR 29.0), QT prolongation (4.5), cardiac arrhythmias (2.2) and heart failure (2.2).

SPS commentary:

The authors note that cardiovascular adverse events associated with use of hydroxychloroquine or chloroquine were associated with hospitalisation rates of 39% and mortality rates of 8%, and they caution that its off-label use should be carefully considered.

British Journal of Clinical Pharmacology